VISTEON CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that VISTEON CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.77B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.87B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $3.95B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $3.76B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $2.77B | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $2.55B | Feb 16, 2023 |
| FY2019 | Dec 31, 2019 | $744.00M | Feb 20, 2020 |
| FY2019 | Sep 30, 2019 | $731.00M | Feb 20, 2020 |
| FY2019 | Jun 30, 2019 | $733.00M | Feb 20, 2020 |
| FY2019 | Mar 31, 2019 | $737.00M | Feb 20, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $1.96B | Feb 25, 2014 |
| FY2013 | Sep 30, 2013 | $1.73B | Feb 25, 2014 |
| FY2013 | Jun 30, 2013 | $1.89B | Feb 25, 2014 |
| FY2013 | Mar 31, 2013 | $1.86B | Feb 25, 2014 |
| FY2013 | Dec 31, 2012 | $1.82B | Feb 25, 2014 |
| FY2013 | Sep 30, 2012 | $1.62B | Feb 25, 2014 |
| FY2013 | Jun 30, 2012 | $1.69B | Feb 25, 2014 |
| FY2013 | Mar 31, 2012 | $1.72B | Feb 25, 2014 |
| FY2013 | Dec 31, 2011 | $7.53B | Feb 25, 2014 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $532.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $531.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $487.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $368.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $254.00M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $245.00M | Feb 16, 2023 |
| FY2019 | Dec 31, 2019 | $104.00M | Feb 20, 2020 |
| FY2019 | Sep 30, 2019 | $84.00M | Feb 20, 2020 |
| FY2019 | Jun 30, 2019 | $70.00M | Feb 20, 2020 |
| FY2019 | Mar 31, 2019 | $66.00M | Feb 20, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.00M | Feb 19, 2026 |
| FY2025 | Sep 30, 2025 | ($11.00M) | Feb 19, 2026 |
| FY2025 | Jun 30, 2025 | $71.00M | Feb 19, 2026 |
| FY2025 | Mar 31, 2025 | $67.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $125.00M | Feb 19, 2026 |
| FY2025 | Sep 30, 2024 | $40.00M | Feb 19, 2026 |
| FY2025 | Jun 30, 2024 | $83.00M | Feb 19, 2026 |
| FY2025 | Mar 31, 2024 | $48.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $568.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $124.00M | Feb 18, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $220.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $191.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $210.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $196.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $191.00M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $201.00M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $300.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $286.00M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $253.00M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $295.00M | Feb 21, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $202.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $207.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $207.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $188.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $175.00M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $193.00M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $221.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $193.00M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $226.00M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $224.00M | Feb 21, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $410.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $427.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $267.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $167.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $58.00M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $168.00M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $183.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $204.00M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $215.00M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $116.00M | Feb 21, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $142.00M | Feb 20, 2020 |
| FY2019 | Dec 31, 2018 | $127.00M | Feb 20, 2020 |
| FY2019 | Dec 31, 2017 | $99.00M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $75.00M | Feb 21, 2019 |
| FY2017 | Dec 31, 2015 | $187.00M | Feb 22, 2018 |
| FY2016 | Dec 31, 2014 | $340.00M | Feb 23, 2017 |
| FY2015 | Dec 31, 2013 | $269.00M | Feb 25, 2016 |
| FY2014 | Dec 31, 2012 | $229.00M | Feb 26, 2015 |
| FY2013 | Dec 31, 2011 | $258.00M | Feb 25, 2014 |
| FY2011 | Dec 31, 2009 | $151.00M | Feb 27, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.39B | Feb 19, 2026 |
| FY2025 | Sep 30, 2025 | $3.30B | Feb 19, 2026 |
| FY2025 | Jun 30, 2025 | $3.30B | Feb 19, 2026 |
| FY2025 | Mar 31, 2025 | $3.10B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.97B | Feb 19, 2026 |
| FY2025 | Sep 30, 2024 | $2.99B | Feb 19, 2026 |
| FY2025 | Jun 30, 2024 | $2.83B | Feb 19, 2026 |
| FY2025 | Mar 31, 2024 | $2.83B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $2.73B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $2.45B | Feb 20, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.57B | Feb 19, 2026 |
| FY2025 | Sep 30, 2025 | $1.53B | Feb 19, 2026 |
| FY2025 | Jun 30, 2025 | $1.53B | Feb 19, 2026 |
| FY2025 | Mar 31, 2025 | $1.42B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.33B | Feb 19, 2026 |
| FY2025 | Sep 30, 2024 | $1.29B | Feb 19, 2026 |
| FY2025 | Jun 30, 2024 | $1.21B | Feb 19, 2026 |
| FY2025 | Mar 31, 2024 | $1.14B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.04B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $675.00M | Feb 20, 2024 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $0 | Feb 20, 2020 |
| FY2018 | Dec 31, 2018 | $0 | Feb 21, 2019 |
| FY2017 | Dec 31, 2017 | $47.00M | Feb 22, 2018 |
| FY2017 | Dec 31, 2016 | $45.00M | Feb 22, 2018 |
| FY2016 | Dec 31, 2015 | $40.00M | Feb 23, 2017 |
| FY2015 | Dec 31, 2014 | $46.00M | Feb 25, 2016 |
| FY2014 | Dec 31, 2013 | $97.00M | Feb 26, 2015 |
| FY2014 | Dec 31, 2012 | $46.00M | Feb 26, 2015 |
| FY2013 | Dec 31, 2011 | $36.00M | Feb 25, 2014 |
| FY2011 | Dec 31, 2010 | $38.00M | Feb 27, 2012 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.84B | Feb 19, 2026 |
| FY2025 | Sep 30, 2025 | $2.77B | Feb 19, 2026 |
| FY2025 | Jun 30, 2025 | $2.79B | Feb 19, 2026 |
| FY2025 | Mar 31, 2025 | $2.72B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.65B | Feb 19, 2026 |
| FY2025 | Sep 30, 2024 | $2.53B | Feb 19, 2026 |
| FY2025 | Jun 30, 2024 | $2.49B | Feb 19, 2026 |
| FY2025 | Mar 31, 2024 | $2.40B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $2.27B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $1.79B | Feb 20, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $771.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $623.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $515.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $520.00M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $452.00M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $496.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $466.00M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $463.00M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $706.00M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $878.00M | Feb 22, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 19, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Feb 19, 2026 |
| FY2025 | Jun 30, 2025 | 2 | Feb 19, 2026 |
| FY2025 | Mar 31, 2025 | 2 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 19, 2026 |
| FY2025 | Sep 30, 2024 | 1 | Feb 19, 2026 |
| FY2025 | Jun 30, 2024 | 3 | Feb 19, 2026 |
| FY2025 | Mar 31, 2024 | 1 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 20 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 18, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 19, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Feb 19, 2026 |
| FY2025 | Jun 30, 2025 | 2 | Feb 19, 2026 |
| FY2025 | Mar 31, 2025 | 2 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 19, 2026 |
| FY2025 | Sep 30, 2024 | 1 | Feb 19, 2026 |
| FY2025 | Jun 30, 2024 | 2 | Feb 19, 2026 |
| FY2025 | Mar 31, 2024 | 1 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 19 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 18, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 26.80M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 27.20M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 27.70M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | 28.20M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | 28.00M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | 28.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | 28.00M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | 28.00M | Feb 20, 2020 |
| FY2019 | Dec 31, 2017 | 31.00M | Feb 20, 2020 |
| FY2017 | Dec 31, 2016 | 33.00M | Feb 22, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $0 | Feb 19, 2026 |